Profund Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Profund Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13,942	Closed	-$207K	–	1337
2019 Q2	$207K	Sell	13,942 -1,640	-11%	-$29.6K	0.01%	1125
2019 Q1	$387K	Buy	15,582 +60	+0.4%	+$1.5K	0.02%	768
2018 Q4	$279K	Sell	15,522 -3,974	-20%	-$81.2K	0.02%	798
2018 Q3	$573K	Buy	19,496 +1,692	+10%	+$65.5K	0.02%	702
2018 Q2	$810K	Buy	17,804 +227	+1%	+$11K	0.03%	473
2018 Q1	$928K	Sell	17,577 -1,686	-9%	-$98.4K	0.04%	446
2017 Q4	$1.31M	Sell	19,263 -2,015	-9%	-$141K	0.05%	351
2017 Q3	$1.75M	Buy	+21,278	New	+$1.69M	0.07%	250
2016 Q3	–	Sell	-19,227	Closed	-$264K	–	1483
2016 Q2	$264K	Sell	19,227 -502	-3%	-$7.34K	0.01%	1206
2016 Q1	$379K	Sell	19,729 -4,630	-19%	-$98K	0.02%	925
2015 Q4	$853K	Buy	24,359 +254	+1%	+$16.4K	0.04%	422
2015 Q3	$2.22M	Buy	+24,105	New	+$2.09M	0.13%	114

Other funds holding CLVS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Profund Advisors's CLVS Position: Q3 2019 in Review

Profund Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 13,942 shares — an estimated $207K sold.

Profund Advisors first reported a position in CLVS in Q3 2015 and held it in 12 quarters. The position peaked at $2.22M in Q3 2015. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

Profund Advisors reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
Profund Advisors sold 13,942 Clovis Oncology, Inc. shares in Q3 2019, an estimated $207K.
Profund Advisors first reported a position in Clovis Oncology, Inc. in Q3 2015 and held it in 12 quarters.
Profund Advisors's Clovis Oncology, Inc. position peaked at $2.22M in Q3 2015.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on Profund Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.